Aging and cardiac implantable electronic device complications: is the procedure safe in older patients?

Tuncay Güzel1, Adem Aktan2, Raif Kılıç3

  • 1Department of Cardiology, Health Science University, Gazi Yaşargil Training and Research Hospital, 21070, Diyarbakır, Turkey. drtuncayguzel@gmail.com.

Insights

Older patients (≥75 years) undergoing cardiac implantable electronic device (CIED) procedures had higher infection rates. Careful pre- and post-procedure evaluation for infection is crucial in this demographic.

Area of Science:

  • Cardiology
  • Medical Devices
  • Geriatric Medicine

Background:

  • Cardiac implantable electronic devices (CIEDs) are crucial for managing various cardiac conditions.
  • Assessing procedural complication risks in elderly populations is vital for patient safety.
  • This study compares complication incidence in patients aged ≥75 years versus <75 years undergoing CIED procedures.

Purpose of the Study:

  • To determine if older patients (≥75 years) experience a higher incidence of complications following cardiac implantable electronic device (CIED) procedures compared to younger patients (<75 years).

Main Methods:

  • A retrospective cohort study was conducted involving 1923 patients who underwent CIED procedures between January 2011 and May 2023.
  • Patients were stratified into two groups: <75 years and ≥75 years.
  • The primary composite endpoint included clinically significant hematoma, pericardial effusion/tamponade, pneumothorax, and device-related infection.

Main Results:

  • No significant difference was observed in the overall primary composite endpoint between the age groups (3.5% vs. 4.4%, p=0.393).
  • Device-related infection rates were significantly higher in the older group (1.8% vs. 3.4%, p=0.034).
  • No significant differences were found for clinically significant hematoma or pneumothorax between the age groups.

Conclusions:

  • Infection rates were notably higher in patients aged 75 years and older.
  • This elderly patient group requires heightened vigilance for infection development, both before and after CIED procedures.
  • Multivariate analysis did not identify age ≥75 years as an independent risk factor for device-related infection.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
565
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K